Navigation Links
STERRAD(R) CYCLESURE(R) Biological Indicator is now 24 Hours, Accelerating Instrument Throughput
Date:1/12/2009

IRVINE, Calif., Jan. 12 /PRNewswire/ -- Advanced Sterilization Products (ASP) is pleased to announce that its STERRAD(R) CYCLESURE(R) Biological Indicator readout time has significantly improved from a 48 hour incubation time to only 24 hours. Now, STERRAD(R) System customers can safely record biological indicator results in 50% less time, speeding up instrument throughput in the sterilization department. The product name is also changing to STERRAD(R) CYCLESURE(R) 24 Biological Indicator to reflect this time-saving improvement.

ASP successfully re-engineered the product after receiving feedback from customers requesting a faster incubation period. A faster incubation period keeps sterilization departments moving efficiently as well as limiting the need to purchase duplicate instrument inventories, which is frequently required when waiting for the results of a 48 hour or more biological indicator readout.

"ASP has been providing healthcare organizations with STERRAD(R) System technology and supplies for almost two decades," says Karen Borg, Worldwide Vice President of Marketing for ASP. "We are committed to continuous product innovation and are passionate about designing and marketing infection prevention solutions like the STERRAD(R) CYCLESURE(R) 24 Biological Indicator that not only meet our customers' needs, but often exceed them."

The STERRAD(R) CYCLESURE(R) 24 Biological Indicator can be used with all of ASP's market-leading, low-temperature hydrogen peroxide gas plasma STERRAD(R) Systems: the STERRAD(R) 100NX(TM) System, STERRAD(R) NX(TM) System, STERRAD(R) 100S System, STERRAD(R) 200 System, as well as the STERRAD(R) 50 System. The STERRAD(R) CYCLESURE(R) 24 Biological Indicator is only validated for use in STERRAD(R) Systems.

For information about STERRAD(R) System products, ASP or ASP's line of infection prevention solutions, visit www.sterrad.com or call 1-888-STERRAD.

About ASP

Advanced Sterilization Products (ASP), division of Ethicon, Inc., a Johnson & Johnson company, has a long track record of designing and delivering innovative infection prevention solutions that dramatically raise the level of health and safety for those who matter most. Our pioneering technology, global distribution, and established leadership position enable us to simplify the process of buying and operating infection prevention products and services every day, for thousands of medical facilities around the world. This in turn enables our customers to focus on what they do best - preventing infection and saving lives.

www.sterrad.com

    For Information Contact:

    Scott Shadiow                              Katie Sweet
    Dorland Global Public Relations            ASP
    415-262-5206 (office)                      949-789-3945 (office)
    sshadiow@dorland.com                       ksweet@its.jnj.com


'/>"/>
SOURCE Advanced Sterilization Products
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ASP Launches STERRAD(R) Sterility Guide - Eliminating Paperwork and Ensuring Compliance
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Study questions assumptions about human sensitivity to biological motion
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
8. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
9. Biological markers of prostate cancer shed light on cancer burden faced by African-American men
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Biological Link Between BRCA1 and Breast Cancer Detailed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... MD (PRWEB) , ... May 04, 2016 , ... ... Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy ... event promotion, time saving and planning tools to attendees and exhibitors for the ...
(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 According to market research ... Growth and Demand Forecast to 2022 - Industry Insights ... Field, Very High Field, Low to Mid Field, and ... Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and ... (MRI) market was valued at $5,351.7 million in 2015, ...
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: